The role of IL-4 and IL-10 cytokines in controlling an anti-tumor response in vivo

International Immunology

Volumn 10, Issue 6, 1998, Pages 823-832

  Terres, Geronimo ^a   Coffman, Robert L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cytotoxic T lymphocyte; IL 10; IL 4; NK cells; Tumor immunity

Indexed keywords

CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SPLENOMEGALY; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; FEMALE; INTERLEUKIN-10; INTERLEUKIN-4; KILLER CELLS, NATURAL; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEUTROPHILS; RATS; RECOMBINANT PROTEINS; SPLEEN; SUPPRESSOR FACTORS, IMMUNOLOGIC; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031841077     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/10.6.823     Document Type: Article

References (26)

1. Heinzel, F. P., Sadick, M. D., Holaday, B. J., Coffman, R. L. and Locksley, R. M. 1989. Reciprocal expression of interferon gamma and interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59.
2. Scott, P. 1991. IFN-gamma modulates the early development of Th1 and Th2 responses in murine model of cutaneous leishmaniasis. J. Immunol. 147:3149.
3. Chatelain, R., Varkila, K. and Coffman, R. L. 1992 IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:1182.
4. Pennline, K. J., Roque-Gaffney, E. and Monahan, M. 1994. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol. 71:169.
5. Tepper, R. I., Pattengale, P. K. and Leder, P. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
6. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M. and Pardoll, D. M. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
7. Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399.
8. Suzuki, T., Tahara, H., Narula, S., Moore, K. W., Robbins, P. D. and Lotze, M. T. 1995. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL10 homologue, induces local anergy to allogeneic and syngeneic tumors. J. Exp. Med. 182:477.
9. Azuma, M., Cayabyab, M., Buck, D., Phillips, J. H. and Lanier, L. L. 1992. CD28 interaction with B7 costimulates primary allogeneic prolferation responses and cytotoxicity mediated by small, resting T lymphocytes. J. Exp. Med. 175:353.
10. Finkelman, F. D., Madden, K. B., Morris, S. C., Holmes, J. M., Boiani, N., Katona, I. M. and Maliszewski, C. R. 1993. Anti-cytokine antibodies as carrier protein. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. 151:1235.
11. Basten, A. and Beeson, P. B. 1970. Mechanism of eosinphilia. II. Role of lymphocytes. J. Exp. Med. 131:1288.
12. Bosco, M., Giovarelli, M., Forni, M., Modesti, A., Scarpa, S., Masuelli, L. and Forni, G. 1990. Low does of IL4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145:3136.
13. Li, W., Diamanstein, T. and Blankenstein, T. 1990. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol Immunol. 27:1331.
14. Tepper, R. I., Coffman, R. L. and Leder, P. 1992. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257:548.
15. Wang, L., Goillot, E. and Tepper, R. I. 1994. IL10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo. Cell. Immunol. 159:152.
16. + T cells. Immunity 1:553.
17. Powrie, F., Menon, S. and Coffman, R. L. 1993. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 23:2223.
18. Tunru, I. S., Suzuki, H. and Yano, S. 1991. Effect of macrophages on interleukin-2 (IL2) and IL4-induced murine lymphokine-activated killer activity. Int. J. Cancer 48:568.
19. Mule, J. J., Smith, C. A. and Rosenberg, S. A. 1987. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J. Exp Med. 166:792.
20. Peace, D. J., Kern, D. E., Schultz, K. R., Greenberg, P. D. and Cheever, M. A. 1988. IL4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes. J. Immunol. 140:3679.
21. Mule, J. J., Krosnick, J. A. and Rosenberg, S. A. 1989. IL4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL2 induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. J. Immunol. 142:726.
22. Cassatella, M. A., Meda, L., Gasperini, S., D'Andrea, A., Ma, X. and Trinchieri, G. 1995. Interleukin-12 production by human polymorphonuclear leukocytes. Eur. J. Immunol. 25:1.
23. Romani, L., Mencacci, A., Cenci, E., Spaccapelo, R., Del Sero, G., Nicoletti, I., Trinchieri, G., Bistoni, F. and Puccetti, P. 1997. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J. Immunol. 158:5349.
24. D'Andrea, A., Ma, X., Aste-Amezaga, M., Paganin, C. and Trinchieri, G. 1995. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J. Exp Med. 181:537.
25. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen specific adaptive immunity. Annu Rev. Immunol. 13:251.
26. Allavena, P., Paganin, C., Zhou, D., Bianchi, G., Sozzani, S. and Mantovani, A. 1994. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood 84:2261.